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Background: Atypical hemolytic uremic syndrome (aHUS) is a rare genetic life-threatening disease of
chronic uncontrolled complement activation leading to thrombotic microangiopathy (TMA) and severe end-
organ damage. Eculizumab, a terminal complement inhibitor approved for aHUS treatment, was reported to
improve hematologic and renal parameters in 2 prior prospective phase 2 studies. This is the largest
prospective study of eculizumab in aHUS to date, conducted in an adult population.
Study Design: Open-label single-arm phase 2 trial.
Setting & Participants: Patients18yearsorolderwithaHUS(platelet count,1503103/mL,hemoglobin# lower
limit of normal, lactate dehydrogenase $1.5 3 upper limit of normal [ULN], and serum creatinine $ ULN) were
included in this multicenter multinational study.
Intervention: Intravenous eculizumab (900 mg/wk for 4 weeks, 1,200 mg at week 5 and then every
2 weeks) for 26 weeks.
Outcomes & Measurements: Primary end point was complete TMA response within 26 weeks, defined as
hematologic normalization (platelet count $150 3 103/mL, LDH # ULN), and preservation of kidney function
(,25% serum creatinine increase from baseline), confirmed by 2 or more consecutive measurements obtained
4 or more weeks apart.
Results: 41 patients were treated; 38 (93%) completed 26weeks of treatment. 30 (73%)were included during
their first TMA manifestation. 30 (73%) had complete TMA response. Platelet counts and estimated glomerular
filtration rates increased frombaseline (P, 0.001).All 35patientsonbaselineplasmaexchange/plasma infusion
discontinued by week 26. Of 24 patients requiring baseline dialysis, 5 recovered kidney function before eculi-
zumab initiation and15of the remaining19 (79%)discontinueddialysis during eculizumab treatment. No patients
lost existing transplants. Quality-of-life measures were significantly improved. Two patients developed
meningococcal infections; both recovered, and 1 remained on eculizumab treatment.
Limitations: Single-arm open-label design.
Conclusions: Results highlight the benefits of eculizumab in adult patients with aHUS: improvement in
hematologic, renal, and quality-of-life parameters; dialysis discontinuation; and transplant protection.
Am J Kidney Dis. 68(1):84-93.ª 2016 The Authors. Published by Elsevier Inc. on behalf of the National Kidney
Foundation, Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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Eculizumab in Adults With aHUSAtypical hemolytic uremic syndrome (aHUS) is arare, often progressive, and life-threatening
cause of systemic thrombotic microangiopathy
(TMA) resulting from long-term uncontrolled alter-
native complement activation.1-3 Complement gene
mutations or factor H autoantibodies have been
identiﬁed in up to 70% of patients with aHUS,4-6 but
are not required for diagnosis. Although frequently
diagnosed during childhood, the majority (58%) of
aHUS cases occur in patients older than 18 years.5
The underlying pathophysiology associated with
aHUS involves endothelial cell activation, platelet acti-
vation and aggregation, leukocyte recruitment, and a
systemic procoagulant state, leading to TMA.3,4,6-8
Decreased kidney function and end-stage renal disease
(ESRD) are recognized as severe complications of aHUS.
Forty-six percent of patients have already reached ESRD
by the time aHUS is diagnosed,5 and the risk for kidney
failure and death increases with disease duration.4,5 More
rarely, TMA in aHUS also leads to signiﬁcant morbidity
in other vital organ systems, including neurologic,
cardiovascular, pulmonary, and gastrointestinal.1,9
Historically, management of aHUS has included
plasma exchange/plasma infusion (PE/PI), yet outcomes
for adultswith aHUS receiving PE/PI are poor; up to 56%
progress to ESRD or die within 1 year of diagnosis.5 The
longer term outlook is equally dire because up to 79% of
patients have permanently decreased kidney function or
ESRD or die within 3 years.4 Kidney transplantation in
patients with aHUS historically also has been unsuc-
cessful because approximately 50% to 71% of patients
with aHUShave transplant failurewithin 1 year as a result
of a subsequent TMA manifestation.4,10
Eculizumab (Soliris; Alexion Pharmaceuticals, Inc) is
a humanized monoclonal antibody that blocks cleavage
of the terminal complement protein C5 into the proin-
ﬂammatory C5a and lytic C5b-9.6,11 In 2011, eculizu-
mab became the ﬁrst and only approved treatment for
aHUS.12,13 The efﬁcacy and safety of eculizumab in
aHUS were ﬁrst demonstrated in 2 prospective clinical
trials of primarily adult patients, either with evidence of
progressing TMA or with long disease duration and
chronic kidney disease (CKD).14,15 Both pivotal trials
included patients with native kidneys and kidney trans-
plants.14 The current study is theﬁrst and largest study of
eculizumab in an exclusively adult population with se-
vere aHUS and was conducted to satisfy requirements
for full approval in the United States. This report pre-
sents results of the primary analysis based on a 26-week
eculizumab treatment period.
METHODS
Study Design and Approval
This was an open-label, single-arm, multicenter, phase 2 trial in
adult patients with aHUS to assess the efﬁcacy of eculizumab in
inhibiting complement-mediated TMA. The study consisted of aAm J Kidney Dis. 2016;68(1):84-937-day screening period, 26-week treatment period, and an exten-
sion period in which patients could receive eculizumab for up to
2 years. Patients 18 years or older with aHUS, platelet
counts ,150 3 103/mL, hemoglobin levels at or less than the
lower limit of normal range, lactate dehydrogenase (LDH)
levels $ 1.5 times the upper limit of normal range, and serum
creatinine levels at or greater than the upper limit of normal range
at screening were enrolled at 23 centers in North America and
Europe from August 2010 through September 2011. An identiﬁed
complement abnormality was not required for enrollment,
although complement mutation analysis was performed in all
patients upon study entry. Use of PE/PI was not a prerequisite for
inclusion. Patients must have been vaccinated against Neisseria
meningitidis; if vaccination occurred fewer than 14 days prior to
receiving the ﬁrst eculizumab dose, patients received prophylactic
antibiotics until at least 14 days after vaccination. Key exclusion
criteria were described previously.14
The protocol was approved by the institutional review board at
each participating center or by an independent ethics committee
(Table S1, available as online supplementary material) and was
conducted in accordance with International Council for Harmo-
nisation of Technical Requirements for Pharmaceuticals for Human
Use Guidelines and the Declaration of Helsinki. All patients pro-
vided written informed consent before entry into the study.
Dosages
Eculizumab dosages were based on previous clinical studies14
and were administered intravenously at 900 mg once a week for
4 weeks, 1,200 mg at week 5, and then 1,200 mg every 2 weeks.
Patients who discontinued eculizumab therapy were followed up
for 8 weeks to assess safety parameters and for 1 year to assess
aHUS disease status and outcomes.
End Points
Efﬁcacy end points were within 26 weeks of the treatment (pri-
mary analysis) and were deﬁned elsewhere14 unless speciﬁed here.
The primary end point was proportion of patients who achieved
complete TMA response, deﬁned as hematologic normalization
(platelet count $150 3 103/mL and LDH # upper limit of normal
range) and preservation of kidney function (,25% increase in
serum creatinine from baseline), conﬁrmed by 2 or more consecu-
tive measurements obtained 4 or more weeks apart. Secondary end
points included modiﬁed complete TMA response, deﬁned as he-
matologic normalization (platelets and LDH) and improvement in
kidney function (ie, $25% decrease in serum creatinine level from
baseline), TMA event-free status (absence of platelet count decrease
. 25% from baseline, PE/PI, and new dialysis for $12 weeks),
TMA intervention rate (number of PE/PI and/or new dialysis events
per patient-days), hematologic normalization, and improvements in
hematologic parameters (platelet count, LDH, and hemoglobin
levels) and kidney function measures (estimated glomerular ﬁltra-
tion rate [eGFR]16 and CKD improvement by $1 stage). Categor-
ical end points were required to be sustained for 2 or more
consecutive measurements obtained 4 or more weeks apart. All
enrolled patients were included in analyses of response variable end
points (eg, complete TMA response, modiﬁed complete TMA
response, TMA event-free status, platelet count normalization, LDH
normalization, hematologic normalization, improvement in hemo-
globin level by $2 g/dL, eGFR improvement by $15 mL/min/
1.73 m2, and CKD improvement by $1 stage). If a patient did not
have sufﬁcient data to meet the achievement criteria for a response
variable end point and sustain achievement for 28 days, the patient
could not achieve the end point. Data may be missing if patients did
not attend the week 26 visit or no measurement was recorded for the
following continuous variables: mean change from baseline in
platelet count and eGFR, mean eGFR and serum creatinine level,
and CKD stage. Health-related quality of life was assessed by the85
Adults (age ≥18 years) with clinical 
diagnosis of aHUS with:
• Platelet count <150 x 103/μL
• Hemoglobin level ≤ULN
• LDH level ≥1.5 ULN
• Serum creatinine level ≥ULN
44 Patients were enrolled
41 Were treated with eculizumab
38 Completed 26 weeks of treatment
3 Withdrew
(SAEa; lack of 
efficacyb; pregnancy)
Figure 1. Patient disposition. aPatient with meningococcal
meningitis who recovered but permanently discontinued the
study. bEighty-year-old patient who had complete thrombotic
microangiopathy response (ie, normalization of platelets, lactate
dehydrogenase [LDH], and preservation of kidney function
with ,25% increase in serum creatinine from baseline) on
eculizumab therapy. However, the patient’s serum creatinine
level did not decrease and hemoglobin level did not normalize.
The patient was withdrawn from the study on day 104. Abbrevi-
ations: aHUS, atypical hemolytic uremic syndrome; SAE,
serious adverse event; ULN, upper limit of the normal range.
Fakhouri et alEQ-5D (EuroQol Group) US time trade-off17 as described previ-
ously,14 the Functional Assessment of Chronic Illness Therapy–
Fatigue (FACIT-F),18 and the 36-Item Short Form Health Survey
(SF-36)19 questionnaires. The safety and tolerability of eculizumab
was assessed by reported adverse events (AEs), reviewed by an
independent data monitoring committee. The presence of neutral-
izing human anti-human antibodies was assessed at study days
0 and 28 and at the end of study with an electrochemiluminescence
bridging assay, which conjugated eculizumab to biotin and to
SulfoTag (Meso Scale Diagnostics, LLC).
Statistical Analyses
All analyses were performed for the intention-to-treat population,
deﬁned as all patients who received 1 or more dose of eculizumab,
using the SAS System (version 9.2; SAS Institute Inc). Statistical tests
were assessed at the 2-sided a5 5% level without adjustment for
multiplicity. Complete TMA response, modiﬁed complete TMA
response, and proportion of patients with a $15 mL/min/1.73 m2
change in eGFRwere assessed using the Clopper-Pearsonmethod for
responder rate at the 1-sided a5 5% level. For all composite end
points, patients were censored at the last follow-up day if baseline or
postbaseline values were missing for any component; patients unable
to be assessed for all components were considered treatment failures.
Effect size for the EQ-5D was calculated as Cohen d standardized
mean change from baseline. Baseline demographic and clinical
characteristics andefﬁcacyoutcomesof subgroupsofpatientswhodid
and did not require dialysis at study baseline were analyzed post hoc.
RESULTS
Patients
Forty-four adult patients were enrolled, 41 were
treated, and 38 (93%) completed the 26-week study
period (Fig 1). Patient demographics, disease charac-
teristics, and baseline laboratory values in the intention-
to-treat population and for patientswhodid (n5 24) and
did not (n5 17) require dialysis use at baseline are
summarized in Table 1. The study population was
mainly white (93%) and female (68%), with a mean age
of 40 years. Twenty-one (51%) patients had 1 or more
identiﬁed complement genetic mutation, autoantibody,
or deletion. Thirty (73%) patients had aHUS newly
diagnosed and were enrolled in the study during their
ﬁrst clinical TMA manifestation. Thirty-ﬁve (85%) pa-
tients received eculizumab after undergoing PE/PI dur-
ing the current manifestation; 6 (15%) received ﬁrst-line
eculizumab without prior PE/PI. Twenty-four (59%)
patients were on dialysis at baseline for a median pre-
treatment duration of 13 (range, 2-2,376) days
(measured in 20 patients; the other 4 initiated dialysis
between days 0 and 14), including 13 (range, 2-26) days
during the current manifestation (n5 18). Nine (22%)
patients had a history of prior kidney transplantation.
Efﬁcacy
Primary End Point
There was complete TMA response in 30 patients
(73%;95%conﬁdence interval [CI], 57%-86%;N5 41)
by 26 weeks (Table 2). Criteria for the primary end point
were met by 17 of 24 (71%) patients requiring dialysis86and 13 of 17 (77%) who did not require dialysis
at baseline. Overall, median time to complete TMA
response was 56 (range, 2-147) days.
Other TMA Outcomes
By 26 weeks, modiﬁed complete TMA response
was achieved by 23 patients (56%; 95% CI, 40%-72%;
N 5 41) at a median of 57 (range, 2-147) days. TMA
event-free status was reached by 37 patients (90%;
95% CI, 77%-97%; N 5 41; Table 2) after a mean of
6.16 14.3 (standard deviation) days. The median
TMA intervention rate signiﬁcantly decreased from
0.6 (range, 0-1.4) per patient before treatment to
0 (range, 0-0.6) per patient while on eculizumab
therapy (P , 0.001). Of 35 patients on PE/PI at
baseline, all (100%) discontinued PE/PI during the
study period (range, day 0-163). Four of the 6 patients
not receiving PE/PI at baseline initiated PE/PI during
the study period. However, no patients who remained
on eculizumab treatment at week 26 were receiving
PE/PI.
Hematologic Outcomes
Forty patients (98%; 95% CI, 87%-100%; N 5 41)
had platelet count normalization (Table 2) at a medianAm J Kidney Dis. 2016;68(1):84-93
Table 1. Patient Demographics and Baseline Clinical Characteristics
Variable ITT Population (N 5 41) Dialysisa (n 5 24) No Dialysisa (n 5 17)
Age, y
Mean 40 6 15 35 6 13 48 6 15
Range 18-80 18-65 27-80
Age category
18-44 y 27 (66) 19 (79) 8 (47)
45-65 y 12 (29) 5 (21) 7 (41)
.65 y 2 (5) 0 (0) 2 (12)
Female sex 28 (68) 17 (71) 11 (65)
Race/ethnicity
White 38 (93) NA NA
Black or African American 2 (5) NA NA
Asian 1 (2) NA NA
Patient-reported family history of aHUS 6 (15) 4 (17) 2 (12)
Identified complement gene mutation or autoantibody 20 (49) 13 (54) 7 (41)
CFH 10 (24) 9 (38) 1 (6)
C3 gain-of-function 4 (10) 1 (4) 3 (18)
CFI 2 (5) 0 (0) 2 (12)
MCP 2 (5) 2 (8) 0 (0)
CFH and MCP 1 (2) 0 (0) 1 (6)
CFH autoantibody 1 (2) 1 (4) 0 (0)
Identified CFHR3-CFHR1 deletion 1 (2) 1 (4) 0 (0)
Time from aHUS diagnosis until screening, mo 0.8 (0-311) 0.5 (0-136) 19 (0-311)
Duration of current clinical manifestation of aHUS, mo 0.5 (0-19) 0.4 (0-1) 1 (0-19)
Newly diagnosed 30 (73) 23 (96) 7 (41)
PE/PI during current manifestation 35 (85) 22 (92) 13 (76)
Dialysis at baselinea 24 (59) 24 (100) 0 (0)
Duration of prebaseline dialysis, d 13 (2-2,376)b 13 (2-2,376)b —
Prior kidney transplant 9 (22) 3 (13) 6 (35)
Platelet count (3103/mL) 1196 66 108 6 75 1356 50
Platelet count , 150 3 103/mL 27 (66) 18 (75) 9 (53)
LDH, U/L 4936 501 572 6 628 3816 194
LDH . ULN 32 (78) 19 (79) 13 (77)
Hemoglobin, g/dL, n 5 38 8.76 2.1 8.2 6 1.4 9.76 1.7
Serum creatinine, mg/dL, n 5 40 4.66 3.0 6.0 6 3.2 2.96 1.5
eGFR, mL/min/1.73 m2 17 6 12 10 6 3 27 6 13
eGFR category
,15 mL/min/1.73 m2 27 (66) 23 (96) 4 (24)
15-29 mL/min/1.73 m2 6 (15) 1 (4) 5 (29)
30-44 mL/min/1.73 m2 6 (15) 0 (0) 6 (35)
45-59 mL/min/1.73 m2 2 (5) 0 (0) 2 (12)
Note: Unless otherwise indicated, values for categorical variables are given as number (percentage); values for continuous variables, as
mean6 standarddeviationormedian (range).Conversion factors for hemoglobin ing/dL tog/L,310; serumcreatinine inmg/dL tommol/L,388.4.
Abbreviations: aHUS, atypical hemolytic uremic syndrome;CFH, complement factor H;CFHR, CFH-related protein;CFI, complement factor I;
eGFR, estimated glomerular filtration rate; ITT, intention-to-treat; LDH, lactate dehydrogenase; MCP, membrane cofactor protein; NA, not
available; PE/PI, plasma exchange/plasma infusion; ULN, upper limit of the normal range.
aPatients were grouped by dialysis use at study baseline. Baseline dialysis was defined as any occurring within 7 days prior to and up
to 14 days after the first eculizumab dose.
bIn the 20 patients who discontinued dialysis during the study.
Eculizumab in Adults With aHUSof 8 (range, 0-84) days. Improvement in platelet
counts from baseline was signiﬁcant at 1 week (mean
change, 104 6 115 3 103/mL) and was maintained
to 26 weeks (mean change from baseline,
1356 114 3 103/mL; n 5 27; P # 0.001 at all time
points; Fig 2). There was LDH level normalization
in 37 patients (90%; 95% CI, 77%-97%; N 5 41)
at a median of 54 (range, 2-146) days. At 26
weeks, mean change from baseline in LDH levelsAm J Kidney Dis. 2016;68(1):84-93was 23236 590 U/L (P 5 0.008; n 5 28). There
was hematologic normalization in 36 patients (88%;
95% CI, 74%-96%; N 5 41) by 26 weeks, at a me-
dian of 55 (range, 2-146) days. A total of 25 patients
(61%; 95% CI, 45%-76%; N 5 41) had an improve-
ment in hemoglobin level of at least 2 g/dL by week
26, at a median of 25 (range, 7-113) days. Mean
change from baseline in hemoglobin level after 26
weeks was 3.36 3.2 g/dL (P , 0.001; n 5 25).87
Table 2. TMA, Hematologic, and Kidney Disease Outcomes for Eculizumab in Adult Patients With aHUS, by 26 Weeks of Treatment
Primary and Secondary End Points ITT Population (N 5 41) Dialysisa (n 5 24) No Dialysisa (n 5 17)
Primary end point
Complete TMA responseb 30 (73%) 17 (71%) 13 (77%)
95% CI 57%-86% 49%-87% 50%-93%
TMA outcomes
Modified complete TMA responseb 23 (56%) 15 (63%) 8 (47%)
95% CI 40%-72% 41%-81% 23%-72%
TMA event-free statusb 37 (90%) 22 (92%) 15 (88%)
95% CI 77%-97% 73%-99% 64%-99%
Hematologic outcomes
Platelet count normalizationb 40 (98%) 23 (96%) 17 (100%)
95% CI 87%-100% 79%-100% 81%-100%
Change from baseline in platelet count, 3103/mL (n5 27)c 1356 114 1636 120 87 6 88
P , 0.001 P , 0.001 P5 0.01
LDH normalizationb 37 (90%) 23 (96%) 14 (82%)
95% CI 77%-97% 79%-100% 57%-96%
Hematologic normalizationb 36 (88%) 22 (92%) 14 (82%)
95% CI 74%-96% 73%-99% 57%-96%
Improvement in hemoglobin by $2 g/dLb 25 (61%) 16 (67%) 9 (53%)
95% CI 45%-76% 45%-84% 28%-77%
Kidney disease outcomes
eGFR improvement by $15 mL/min/1.73 m2b 22 (54%) 15 (63%) 7 (41%)
95% CI 37%-69% 41%-81% 18%-67%
Change from baseline in eGFR, mL/min/1.73 m2 (n5 29)d 29 6 24 35 6 22 20 6 24
P , 0.001 P , 0.001 P5 0.02
eGFR, mL/min/1.73 m2 (n5 29)d 47 6 24 46 6 23 51 6 28
Serum creatinine, mg/dL (n 5 29)d 1.76 0.8 NA NA
Patients on dialysis at baseline who discontinued it 20/24 (83%) 20/24 (83%) —
Discontinued before the initial eculizumab dose, but within the
baseline period
5/24 (21%) 5/24 (21%) —
Discontinued during the study period 15/19 (79%) 15/19 (79%)
Patients not on dialysis at baseline who initiated in study period 4/17 (24%) — 4/17 (24%)
CKD staged
1 2 (5%) 0 (0%) 2 (12%)
2 6 (15%) 5 (21%) 1 (6%)
3a 8 (20%) 6 (25%) 2 (12%)
3b 6 (15%) 2 (8%) 4 (24%)
4 2 (5%) 1 (4%) 1 (6%)
5 5 (12%) 4 (17%) 1 (6%)
Unknown 12 (29%) 6 (25%) 6 (35%)
Note: Unless otherwise indicated, values for categorical variables are given as number (percentage) or n/N (percentage); values for
continuous variables are given as mean6 standard deviation. Complete TMA response was defined as platelet count $150 3 103/mL,
LDH at ULN or less, and,25% increase in serum creatinine from baseline (ie, preservation of kidney function) and was confirmed by 2
or more consecutive measurements obtained 4 or more weeks apart. Modified complete TMA response was defined as platelet
count$150 3 103/mL, LDH at ULN or less, and $25% improvement in serum creatinine level from baseline (ie, improvement in kidney
function). TMA event-free status was defined as the absence of the following for 12 or more weeks: .25% decrease from baseline in
platelet count, PE/PI while receiving eculizumab, and new dialysis. Categorical end points were required to be sustained for 2 or more
consecutive measurements obtained 4 or more weeks apart. Conversion factors for hemoglobin in g/dL to g/L, 310; for serum
creatinine in mg/dL to mmol/L, 388.4.
Abbreviations: aHUS, atypical hemolytic uremic syndrome; CI, confidence interval; CKD, chronic kidney disease; eGFR, estimated
glomerular filtration rate; ITT, intention-to-treat; LDH, lactate dehydrogenase; NA, not available; PE/PI, plasma exchange/plasma
infusion; TMA, thrombotic microangiopathy; ULN, upper limit of normal range.
aPatients were grouped by dialysis use at study baseline. Baseline dialysis was defined as any occurring within 7 days prior to and up
to 14 days after the first eculizumab dose.
bN 5 41. All enrolled patients were included in the analysis. If a patient did not have sufficient data to meet the achievement criteria
for a response variable end point and sustain achievement for 28 days, the patient could not achieve the end point.
cData for 14 of 41 (34%) patients were not available at week 26. Data were missing if the patient did not attend the week 26 visit or no
measurement was recorded.
dData for 12 of 41 (29%) patients were not available at week 26. Data were missing if the patient did not attend the week 26 visit or no
measurement was recorded.
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Figure 2. Improvement in platelet count over 26 weeks of eculizumab treatment. Bars represent standard error. *P # 0.001. Only
n. 5 are shown.
Eculizumab in Adults With aHUSKidney Disease Outcomes
Twenty-two patients (54%; 95% CI, 37%-69%;
N5 41) had eGFR improvement of $15 mL/
min/1.73 m2 by week 26 (Table 2). Signiﬁcant im-
provements in eGFRs from baseline were achieved by0
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standard error. *P # 0.05; yP# 0.01. Only n . 5 are shown.
Am J Kidney Dis. 2016;68(1):84-93week1 (P, 0.05) andweremaintained over 26weeks of
treatment (Fig 3).Mean change frombaseline in eGFRs at
26 weeks was 296 24 mL/min/1.73 m2 (P, 0.001;
n5 29). Improvements in eGFRs were greater for pa-
tients on dialysis at baseline comparedwith thosewhodid13 14 15 16 17 18 19 20 21 22 23 24 25 26
udy Week
63 53 92 73
†
†
†
†
GFR) over 26 weeks of eculizumab treatment. Bars represent
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Fakhouri et alnot require baseline dialysis (Table 2). At week 26, mean
serum creatinine level was 1.76 0.8 mg/dL (n5 29).
During the 26-week study period, 26 patients (63%;
N5 41) improved by 1 or more stage of CKD. Of the
24 patients on dialysis at baseline, 20 (83%) dis-
continued dialysis. Of these, 5 discontinued dialysis
before receiving the initial dose of eculizumab. Of the
other 19 patients, 15 (79%) discontinued before week
26, after a posttreatment median of 29 (range, 1-180)
days. Four of the 19 patients continued dialysis at
week 26 (Fig 4). No patient who discontinued dial-
ysis needed to resume dialysis during the 26-week
study period. Of the 17 patients not on dialysis at
baseline, 4 (24%) initiated new dialysis during
the study (on days 36, 62, 120, and 160), including
2 who discontinued prior to and 2 who remained
on dialysis at week 26. Thus, at week 26, a total of 6
patients (15%) were receiving dialysis, compared
with 19 (46%) at the start of eculizumab therapy.
Health-Related Quality of Life
Patient health-related quality of life was also
improved after 26 weeks of eculizumab therapy
(Fig 5). Thirteen of 23 (57%) evaluable patients met
criteria for clinically important improvements
($0.06)20 on the US time trade-off index in the EQ-
5D questionnaire by 26 weeks, and mean change
from baseline was signiﬁcant (P , 0.001). FACIT-F
and SF-36 score changes from baseline after 26
weeks are presented in Item S1.
Pharmacokinetics and Pharmacodynamics
Pharmacokinetic and pharmacodynamic data are
presented in Item S2.First dose
24 patients on dialysis 
at screening
5 discontinue 
dialysis prior to 
first dose
19 remain on 
dialysis
15 discontinue 
dialysis before 
week 26
4 remain
dialysis
week 2
Figure 4. Dialysis use at ba
90Safety
All patients in the study reported at least 1 treatment-
emergent AE (Table S2). Serious treatment-emergent
AEs were reported by 18 patients (44%; Table S3),
1 of which (meningococcal meningitis; serogroup
unknown) led to a permanent eculizumab therapy
discontinuation at day 98. A serious treatment-
emergent AE of meningococcal sepsis (serogroup B)
was reported in 1 patient, who was hospitalized and
recovered without sequelae; eculizumab treatment
was not interrupted. In both cases of meningococcal
infection, the patients had been immunized against
serogroups A, C, W, and Y, but had not received
long-term antibiotic prophylaxis (see additional de-
tails in Table S4). No deaths or unexpected safety
concerns occurred during the study.
Prior to receiving the ﬁrst dose of eculizumab,
elevated alanine transaminase and aspartate amino-
transferase levels were noted in 14 (34%) and 19
(46%) of 41 patients, respectively. In addition, tran-
sient liver enzyme level elevations were observed
during the study. Most patients had normalization of
enzyme levels during eculizumab treatment; at week
26, 3 of 38 (8%) patients had elevated alanine trans-
aminase levels and 1 of 38 (3%) had elevated aspar-
tate aminotransferase levels.
DISCUSSION
This study, which to our knowledge is the largest
prospective trial of eculizumab in aHUS to date,
demonstrates the efﬁcacy of eculizumab in an exclu-
sively adult population with severe aHUS and
predominantly native kidneys, including patients who17 patients not on 
dialysis at screening
4 initiate new 
dialysis 
2 discontinue 
dialysis before 
week 26
2 remain on 
dialysis at 
week 26
 on 
 at 
6
seline and during the study.
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Figure 5. Mean change from baseline in patient EQ-5D United States time trade-off score over 26 weeks of eculizumab treatment.
Bars represent standard error. A change from baseline of 0.06 in EQ-5D score is considered clinically meaningful.20 *P# 0.05;
yP# 0.01. Only n . 5 are shown.
Eculizumab in Adults With aHUShad not received PE/PI prior to enrollment. The
primary end point of complete TMA response was
reached by the majority of patients (73%) after
26 weeks, and high proportions of patients saw
improvements in key hematologic and kidney disease
outcomes. These beneﬁts were observed in patients
who did and did not require dialysis at study baseline.
Importantly, 79% of patients requiring dialysis at
baseline discontinued dialysis after the initiation of
eculizumab therapy.
In addition, improvements in other outcomes
related to the overall well-being of patients with
aHUS, including discontinuation of PE/PI, contribute
to the important clinical beneﬁts of eculizumab. It
should be noted that 4 patients with no history of PE/
PI at baseline initiated new PE/PI during the study
and received it concomitantly with eculizumab ther-
apy for a median duration of 28 (range, 6-81) days.
No patients were on PE/PI at week 26. Due to the
single-arm open-label study design, it was not
possible to evaluate the effects of supportive care in
these particular patients.
The recovery of kidney function and other clinical
beneﬁts shown in the current trial stand in sharp
contrast to the natural history of aHUS. In a large case
series of patients with aHUS before the availability
of eculizumab, 81% of adult patients required
dialysis at onset and 56% could be expected to prog-
ress to ESRD or die in the ﬁrst year after diagnosis
despite the use of PE/PI in a large proportion of theseAm J Kidney Dis. 2016;68(1):84-93patients.5 In the current study, platelet count normal-
ization occurred more rapidly than improvements in
hemoglobin levels or kidney function (ie, serum
creatinine level in modiﬁed complete TMA response),
although signiﬁcant improvements in eGFRs were
seen as early as 1 week after eculizumab therapy
initiation and continued to occur over 26 weeks of
therapy. Although transplantation historically has been
contraindicated in patients with aHUS, no patient who
entered the study with a kidney transplant lost the
transplant after 26 weeks. Together, these ﬁndings
conﬁrm the disease-modifying effects of eculizumab,
including maintenance or improvement of existing
kidney function and protection of kidney transplants.
In the current trial, eculizumab treatmentwas initiated
approximately 1 month after diagnosis, a substantially
shorter duration than in the 2 pivotal trials (which had
median intervals prior to treatment of 9.7 months in
patients with aHUS with progressing TMA and 48.3
months in thosewith long disease duration andCKD).14
Evidence from these pivotal trials14 and case studies of
patients with aHUS6,9 demonstrate that earlier initiation
of eculizumab therapy is associated with signiﬁcantly
greater improvements in kidney disease outcomes. A
larger proportion (54%) of patients in the current study
met criteria for improvement in eGFR by$15 mL/min/
1.73 m2 compared to the pivotal trial of patients with
long disease duration andCKD (5%). The proportion of
patients having this eGFR improvement and overall
change from baseline in eGFR were similar in the91
Fakhouri et alcurrent study and the pivotal study of patients with
progressing TMA.14 Thus, data from the current study
provide further evidence for the recommendation to
diagnose aHUS accurately and quickly and initiate early
treatment with eculizumab in order to prevent rapid
progression and potentially life-threatening conse-
quences of TMA.9
In the current study, beneﬁts of eculizumab were
demonstrated in an adult patient population including
34% with normal platelet counts and 20% with only
moderately reduced kidney function (ie, eGFRs
of 30-59 mL/min/1.73 m2) at baseline. Diagnosis of
aHUS can be particularly complex in adult patients.6
ADAMTS-13 (von Willebrand factor protease)
activity can be evaluated to inform differential diag-
nosis with thrombotic thrombocytopenic purpura.21 It
has been recommended6 that relatively higher serum
creatinine levels (ie,.3.2 mg/dL) or platelet counts (ie,
.30 3 103/mL) at the time of TMA may be predictive
of sufﬁcient ADAMTS-13 levels and lower likelihood
of thrombotic thrombocytopenic purpura diagnosis22;
overall, the relative risk that patients presenting with
TMA and values exceeding these thresholds do not
have severely deﬁcient ADAMTS-13 activity is 21.8
(P. Coppo, personal communication, May 2015). One
should suspect aHUS in all patients with TMA,9,23
even without the most common presenting signs.
Overall, eculizumab was well tolerated in the study
population and no unexpected safety signals or deaths
were noted. The C5b-9 complex confers protection
against encapsulated bacteria, particularly N menin-
gitidis, and its formation is blocked by eculizumab.1
Two cases of meningococcal infection were reported
in the current trial; both patients recovered, and
1 remained on eculizumab therapy. In 1 case, the
meningococcal serogroup was not identiﬁed and thus
it is possible that the vaccine could not have protected
the patient. A vaccine against serogroup B was
recently approved for use in the European Union24
and may provide increased protection against
meningococcal infection for patients with aHUS
treated with eculizumab in the future. No reports of
meningococcal disease have occurred in previous
studies of eculizumab in aHUS, including in the
2-year follow-up of the pivotal trials15 and the
concurrent pediatric trial.25 Based on an analysis of
exposure to eculizumab in a real-world setting,
meningococcal infection may be classiﬁed as an
uncommon event (0.6 event/100 patient-years on
eculizumab therapy in a 10-year study of patients with
paroxysmal nocturnal hemoglobinuria26). However,
these cases highlight the necessity of vaccination
against N meningitidis before eculizumab therapy
initiation and/or prophylactic antibiotic therapy and
for continued vigilance for symptoms of meningo-
coccal infection during therapy.92Elevated liver enzyme levels were noted in some
patients prior to receiving the ﬁrst dose of eculizumab
and also in the postbaseline period in a smaller
number of patients. Overall, there was a strong trend
toward normalization of hepatic enzyme levels after
initiation of eculizumab therapy. These ﬁndings sug-
gest that the increases in alanine transaminase and
aspartate aminotransferase levels that are present after
eculizumab therapy initiation in some patients are
most likely related to the pre-existing TMA. Impor-
tantly, these elevations were not associated with
clinical AEs, and no patient discontinued eculizumab
due to elevated liver enzyme levels or hepatic AEs.
The availability of eculizumab has profoundly
changed the management of aHUS.27 This current
study demonstrates that eculizumab effectively
inhibits complement-mediated TMA, provides signif-
icant clinical beneﬁts for adults with aHUS, and has a
safety proﬁle consistent with that reported from other
clinical studies.14 Results from continued follow-up in
this study and a separate long-term prospective trial
are expected to provide further insights regarding
eculizumab for the treatment of aHUS.
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